ACUS Stock Overview
Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Acusphere, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.000001 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -100.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
ACUS | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | 0.3% | 1.9% |
1Y | n/a | 25.0% | 31.1% |
Return vs Industry: Insufficient data to determine how ACUS performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ACUS performed against the US Market.
Price Volatility
ACUS volatility | |
---|---|
ACUS Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.3% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ACUS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ACUS's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | n/a | n/a | https://www.acusphere.com |
Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension.
Acusphere, Inc. Fundamentals Summary
ACUS fundamental statistics | |
---|---|
Market cap | US$4.00 |
Earnings (TTM) | -US$69.42m |
Revenue (TTM) | US$2.68m |
0.0x
P/S Ratio0.0x
P/E RatioIs ACUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ACUS income statement (TTM) | |
---|---|
Revenue | US$2.68m |
Cost of Revenue | US$34.45m |
Gross Profit | -US$31.77m |
Other Expenses | US$37.65m |
Earnings | -US$69.42m |
Last Reported Earnings
Dec 31, 2008
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did ACUS perform over the long term?
See historical performance and comparison